{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T17:29:43Z","timestamp":1770830983091,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,3,6]],"date-time":"2013-03-06T00:00:00Z","timestamp":1362528000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>To analyse the prognostic significance of preoperative C-reactive protein (CRP) serum level in patients with upper urinary tract urothelial carcinoma (UUT-UC).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We evaluated 158 UUT-UC patients who had undergone surgery in the University Hospital of Hannover (MHH). 143 (89.4%) suffered from cancer in the renal pelvis, 13 (8.1%) patients presented with tumour located in the ureter. A preoperative CRP value was available for 115 patients. The mean (median) follow-up for these patients was 28.3 (15.1) months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The median (mean) CRP value of all evaluable patients was 10.0 (40.7) mg\/l. The CRP-level, stratified into two subgroups (CRP \u22645 vs. &gt;5 mg\/l), correlated significantly with muscle invasive tumour stage (36.4 vs. 78.9%; p&lt;0.001), the risk of presenting nodal disease (4.5 vs. 26.8%; p=0.002) and distant metastasis (2.3 vs. 16.9%; p&lt;0.016). The Kaplan-Meier 5-year cancer specific survival (CSS) rates were 54.2 and 26.4% for patients with preoperative CRP levels \u2264 and &gt;5 mg\/l, respectively (p&lt;0.006). Next to age and the presence of metastasis, multivariate analysis also identified CRP as a continuous variable as an independent prognosticator for CSS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>A high preoperative serum CRP level is associated with locally advanced and metastatic disease in patients with UUT-UC. Its routine use could allow better risk stratification and risk-adjusted follow-up of UUT-UC patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-13-101","type":"journal-article","created":{"date-parts":[[2013,3,6]],"date-time":"2013-03-06T09:20:11Z","timestamp":1362561611000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Preoperative serum C- reactive protein: a prognostic marker in patients with upper urinary tract urothelial carcinoma"],"prefix":"10.1186","volume":"13","author":[{"given":"Barbara","family":"Stein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres Jan","family":"Schrader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerd","family":"Wegener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Seidel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus A","family":"Kuczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Steffens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,3,6]]},"reference":[{"issue":"5","key":"3750_CR1","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/S0022-5347(05)67019-X","volume":"164","author":"JJ Munoz","year":"2000","unstructured":"Munoz JJ, Ellison LM: Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol. 2000, 164 (5): 1523-1525. 10.1016\/S0022-5347(05)67019-X.","journal-title":"J Urol"},{"issue":"Suppl 1","key":"3750_CR2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1159\/000474889","volume":"21","author":"F Corrado","year":"1992","unstructured":"Corrado F, Mannini D, Ferri C, Corrado G, Bertoni F, Bacchini P, Lieber MM, Song JM: The prognostic significance of DNA ploidy pattern in transitional cell cancer of the renal pelvis and ureter: continuing follow-up. Eur Urol. 1992, 21 (Suppl 1): 48-50.","journal-title":"Eur Urol"},{"issue":"4","key":"3750_CR3","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/S0090-4295(98)00295-7","volume":"52","author":"MC Hall","year":"1998","unstructured":"Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG: Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology. 1998, 52 (4): 594-601. 10.1016\/S0090-4295(98)00295-7.","journal-title":"Urology"},{"issue":"6","key":"3750_CR4","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1097\/01.ju.0000181801.22474.8b","volume":"174","author":"E Kikuchi","year":"2005","unstructured":"Kikuchi E, Horiguchi Y, Nakashima J, Hatakeyama N, Matsumoto M, Nishiyama T, Murai M: Lymphovascular invasion independently predicts increased disease specific survival in patients with transitional cell carcinoma of the upper urinary tract. J Urol. 2005, 174 (6): 2120-2123. 10.1097\/01.ju.0000181801.22474.8b. discussion 2124","journal-title":"J Urol"},{"issue":"5","key":"3750_CR5","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S0959-8049(99)00012-X","volume":"35","author":"M Ozsahin","year":"1999","unstructured":"Ozsahin M, Zouhair A, Villa S, Storme G, Chauvet B, Taussky D, Gouders D, Ries G, Bontemps P, Coucke PA: Prognostic factors in urothelial renal pelvis and ureter tumours: a multicentre Rare Cancer Network study. Eur J Cancer. 1999, 35 (5): 738-743. 10.1016\/S0959-8049(99)00012-X.","journal-title":"Eur J Cancer"},{"issue":"2 Pt 1","key":"3750_CR6","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1097\/01.ju.0000107767.56680.f7","volume":"171","author":"S Park","year":"2004","unstructured":"Park S, Hong B, Kim CS, Ahn H: The impact of tumor location on prognosis of transitional cell carcinoma of the upper urinary tract. J Urol. 2004, 171 (2 Pt 1): 621-625.","journal-title":"J Urol"},{"issue":"13","key":"3750_CR7","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1200\/JCO.2008.19.8440","volume":"27","author":"KH Allin","year":"2009","unstructured":"Allin KH, Bojesen SE, Nordestgaard BG: Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol. 2009, 27 (13): 2217-2224. 10.1200\/JCO.2008.19.8440.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3750_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1159\/000093905","volume":"77","author":"PA McArdle","year":"2006","unstructured":"McArdle PA, Mir K, Almushatat AS, Wallace AM, Underwood MA, McMillan DC: Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol Int. 2006, 77 (2): 127-129. 10.1159\/000093905.","journal-title":"Urol Int"},{"issue":"3","key":"3750_CR9","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.juro.2008.10.156","volume":"181","author":"Y Iimura","year":"2009","unstructured":"Iimura Y, Saito K, Fujii Y, Kumagai J, Kawakami S, Komai Y, Yonese J, Fukui I, Kihara K: Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score. J Urol. 2009, 181 (3): 1004-1012. 10.1016\/j.juro.2008.10.156. discussion 1012","journal-title":"J Urol"},{"issue":"4","key":"3750_CR10","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1442-2042.2008.01990.x","volume":"15","author":"N Kawata","year":"2008","unstructured":"Kawata N, Nagane Y, Yamaguchi K, Ichinose T, Hirakata H, Takahashi S: How do symptoms have an impact on the prognosis of renal cell carcinoma?. Int J Urol. 2008, 15 (4): 299-303. 10.1111\/j.1442-2042.2008.01990.x.","journal-title":"Int J Urol"},{"issue":"1","key":"3750_CR11","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1464-410X.2006.06497.x","volume":"99","author":"Y Komai","year":"2007","unstructured":"Komai Y, Saito K, Sakai K, Morimoto S: Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int. 2007, 99 (1): 77-80. 10.1111\/j.1464-410X.2006.06497.x.","journal-title":"BJU Int"},{"issue":"11","key":"3750_CR12","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1111\/j.1442-2042.2006.01563.x","volume":"13","author":"K Ito","year":"2006","unstructured":"Ito K, Asano T, Yoshii H, Satoh A, Sumitomo M, Hayakawa M: Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int J Urol. 2006, 13 (11): 1365-1370. 10.1111\/j.1442-2042.2006.01563.x.","journal-title":"Int J Urol"},{"issue":"5","key":"3750_CR13","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1111\/j.1523-1755.2005.00666.x","volume":"68","author":"WJ Jabs","year":"2005","unstructured":"Jabs WJ, Busse M, Kruger S, Jocham D, Steinhoff J, Doehn C: Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney Int. 2005, 68 (5): 2103-2110. 10.1111\/j.1523-1755.2005.00666.x.","journal-title":"Kidney Int"},{"issue":"6","key":"3750_CR14","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/cncr.22896","volume":"110","author":"PI Karakiewicz","year":"2007","unstructured":"Karakiewicz PI, Hutterer GC, Trinh QD, Jeldres C, Perrotte P, Gallina A, Tostain J, Patard JJ: C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer. 2007, 110 (6): 1241-1247. 10.1002\/cncr.22896.","journal-title":"Cancer"},{"issue":"6","key":"3750_CR15","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/j.1464-410X.2008.07666.x","volume":"102","author":"GW Lamb","year":"2008","unstructured":"Lamb GW, McArdle PA, Ramsey S, McNichol AM, Edwards J, Aitchison M, McMillan DC: The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer. BJU Int. 2008, 102 (6): 756-761. 10.1111\/j.1464-410X.2008.07666.x.","journal-title":"BJU Int"},{"issue":"8","key":"3750_CR16","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1111\/j.1464-410X.2007.07363.x","volume":"101","author":"S Ramsey","year":"2008","unstructured":"Ramsey S, Lamb GW, Aitchison M, McMillan DC: Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer. BJU Int. 2008, 101 (8): 959-963. 10.1111\/j.1464-410X.2007.07363.x.","journal-title":"BJU Int"},{"issue":"1","key":"3750_CR17","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1186\/1471-2407-12-399","volume":"12","author":"S Steffens","year":"2012","unstructured":"Steffens S, Kohler A, Rudolph R, Eggers H, Seidel C, Janssen M, Wegener G, Schrader M, Kuczyk MA, Schrader AJ: Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients. BMC Cancer. 2012, 12 (1): 399-10.1186\/1471-2407-12-399.","journal-title":"BMC Cancer"},{"issue":"2","key":"3750_CR18","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1158\/1055-9965.EPI-05-0626","volume":"15","author":"D Trichopoulos","year":"2006","unstructured":"Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P: Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev. 2006, 15 (2): 381-384. 10.1158\/1055-9965.EPI-05-0626.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"8","key":"3750_CR19","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/j.1464-410X.2007.07408.x","volume":"101","author":"S Yoshida","year":"2008","unstructured":"Yoshida S, Saito K, Koga F, Yokoyama M, Kageyama Y, Masuda H, Kobayashi T, Kawakami S, Kihara K: C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy. BJU Int. 2008, 101 (8): 978-981. 10.1111\/j.1464-410X.2007.07408.x.","journal-title":"BJU Int"},{"issue":"2","key":"3750_CR20","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1464-410X.2007.06934.x","volume":"100","author":"K Saito","year":"2007","unstructured":"Saito K, Kawakami S, Ohtsuka Y, Fujii Y, Masuda H, Kumagai J, Kobayashi T, Kageyama Y, Kihara K: The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU Int. 2007, 100 (2): 269-273. 10.1111\/j.1464-410X.2007.06934.x.","journal-title":"BJU Int"},{"issue":"2","key":"3750_CR21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/ijc.10343","volume":"99","author":"H Nakanishi","year":"2002","unstructured":"Nakanishi H, Araki N, Kudawara I, Kuratsu S, Matsumine A, Mano M, Naka N, Myoui A, Ueda T, Yoshikawa H: Clinical implications of serum C-reactive protein levels in malignant fibrous histiocytoma. Int J Cancer. 2002, 99 (2): 167-170. 10.1002\/ijc.10343.","journal-title":"Int J Cancer"},{"issue":"4","key":"3750_CR22","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/sj.bjc.6602419","volume":"92","author":"K Canna","year":"2005","unstructured":"Canna K, McArdle PA, McMillan DC, McNicol AM, Smith GW, McKee RF, McArdle CS: The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer. 2005, 92 (4): 651-654. 10.1038\/sj.bjc.6602419.","journal-title":"Br J Cancer"},{"issue":"3","key":"3750_CR23","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1385\/IR:30:3:261","volume":"30","author":"TW Du Clos","year":"2004","unstructured":"Du Clos TW, Mold C: C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol Res. 2004, 30 (3): 261-277. 10.1385\/IR:30:3:261.","journal-title":"Immunol Res"},{"issue":"3","key":"3750_CR24","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1006\/gyno.1998.4974","volume":"69","author":"A Maccio","year":"1998","unstructured":"Maccio A, Lai P, Santona MC, Pagliara L, Melis GB, Mantovani G: High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. Gynecol Oncol. 1998, 69 (3): 248-252. 10.1006\/gyno.1998.4974.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"3750_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/BF02482979","volume":"29","author":"K Matsumoto","year":"1999","unstructured":"Matsumoto K, Kinoshita T, Ishida T, Itoh H, Miki C, Suzuki H: Serum levels of NCC-ST-439 in Dukes' C colorectal cancer patients: a preliminary report. Surg Today. 1999, 29 (1): 91-92. 10.1007\/BF02482979.","journal-title":"Surg Today"},{"issue":"12","key":"3750_CR26","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1038\/sj.bjc.6602248","volume":"91","author":"DJ McKeown","year":"2004","unstructured":"McKeown DJ, Brown DJ, Kelly A, Wallace AM, McMillan DC: The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer. Br J Cancer. 2004, 91 (12): 1993-1995. 10.1038\/sj.bjc.6602248.","journal-title":"Br J Cancer"},{"issue":"20","key":"3750_CR27","first-page":"4633","volume":"55","author":"N Borsellino","year":"1995","unstructured":"Borsellino N, Belldegrun A, Bonavida B: Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res. 1995, 55 (20): 4633-4639.","journal-title":"Cancer Res"},{"issue":"2","key":"3750_CR28","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/0014-5793(89)80805-1","volume":"250","author":"S Miki","year":"1989","unstructured":"Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokawa K, Sonoda T, Hirano T, Kishimoto T: Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett. 1989, 250 (2): 607-610. 10.1016\/0014-5793(89)80805-1.","journal-title":"FEBS Lett"},{"issue":"22","key":"3750_CR29","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1093\/jnci\/83.22.1668","volume":"83","author":"J Takenawa","year":"1991","unstructured":"Takenawa J, Kaneko Y, Fukumoto M, Fukatsu A, Hirano T, Fukuyama H, Nakayama H, Fujita J, Yoshida O: Enhanced expression of interleukin-6 in primary human renal cell carcinomas. J Natl Cancer Inst. 1991, 83 (22): 1668-1672. 10.1093\/jnci\/83.22.1668.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"3750_CR30","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/(SICI)1097-0215(19970703)72:1<149::AID-IJC21>3.0.CO;2-D","volume":"72","author":"M Okamoto","year":"1997","unstructured":"Okamoto M, Hattori K, Oyasu R: Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro. Int J Cancer. 1997, 72 (1): 149-154. 10.1002\/(SICI)1097-0215(19970703)72:1<149::AID-IJC21>3.0.CO;2-D.","journal-title":"Int J Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-13-101\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-101","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T22:35:09Z","timestamp":1630535709000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-13-101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,6]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["3750"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-13-101","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,6]]},"assertion":[{"value":"15 October 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"101"}}